Inotropes
ApprovedSmall molecule
Inotropes is one of 29 small molecule programs targeting Hypophosphatemia. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Inotropes
AAmsterdam UMC, location VUmc
Approved
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
LCZ696
NovartisPreclinical
Zemplar
AbbViePreclinical
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Coumadin
AAbbott
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Antidiabetic
FFederico II University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypophosphatemia1 trial
Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU
Unknown status·—·Phase 4·NCT04519762·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inotropes. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAmsterdam UMC, location VUmc